Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $96.50
    -3.77 (-3.76%)

    Market Cap: $11.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Halozyme Therapeutics Inc (HALO) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Halozyme Therapeutics (HALO) trades at 17.8x trailing earnings and 6.1x sales. Its P/E of 17.8x is above its 5-year median of 15.8x. Its forward P/E is 10.6x. The median P/E across 7 similar companies is 39.6x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 67.9% higher over the next year. Its free cash flow yield is 8.1%.

    MultipleValue
    P/E (trailing)17.8x
    Forward P/E10.6x
    Price to sales6.1x
    EV/EBITDA16.1x
    Price to FCF12.4x
    EV/FCF14.9x
    PEGN/A
    FCF yield8.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 39.0% below 10.0x.

    MultipleCurrent5-year median10-year median
    P/E17.8x15.8xN/A
    P/S6.1x7.2x10.0x
    P/BN/A26.9x27.2x
    Medians of month-end values through Oct 2026: 58 to 60 months (5-year) and 111 to 120 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 11.3x in 2024 to 53.3x in 2017.

    Year endPriceP/EP/SP/B
    2025$67.3016.3x5.8x162.2x
    2024$47.8111.3x6.0x17.0x
    2023$36.9613.3x5.9x57.8x
    2022$56.9025.6x11.9x46.4x
    2021$40.2120.1x12.9x29.5x
    2020$42.7147.5x22.4x41.0x
    2019$17.73N/A13.0x27.3x
    2018$14.63N/A13.8x8.5x
    2017$20.2653.3x9.1x14.2x
    2016$9.88N/A8.6xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HALO

    What is HALO's forward P/E ratio?

    Halozyme Therapeutics has a forward P/E ratio of 10.6x.

    Is HALO stock overvalued?

    GNG's valuation label for HALO is Undervalued. Its P/E of 17.8x compares with a median of 39.6x across 7 similar companies.

    What is HALO's price to sales ratio?

    Halozyme Therapeutics has a price to sales ratio of 6.1x.

    What is Halozyme Therapeutics's average P/E ratio over 5 years?

    Halozyme Therapeutics's median P/E over the last 5 years is 15.8x, from 60 month-end values through Oct 2026.